Eli Lilly and Co
Eli Lilly Stock Looks Like a Buy on Dips Amid Strong Growth Outlook
Eli Lilly Will Buy Prevail Therapeutics, COVID-19 Antibody Therapy Is Promising
Merck & Co.’s Animal Health Segment
The revenues of Merck & Co.’s Animal Health segment have improved due to increased sales in the Companion Animal Products segment.
Eli Lilly’s 1Q18 Earnings by Segment
Eli Lilly’s (LLY) products are classified into two business segments: Human Pharmaceutical Products and Animal Health Products.
Is Novo Nordisk Trading at a Discount or Premium?
For the last five years, Novo Nordisk (NVO) has been trading at higher multiples when compared with peers.
A Look at Johnson & Johnson’s Post-2Q17 Valuation
Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.
Lilly’s Total Returns Are Lower than Some Pharma ETFs
The total return for Lilly’s share price on the NYSE from July 2010 to June 2015 has been around 17.9%. This is lower than a few of the pharmaceutical ETFs.
Eli Lilly’s Immunology Business Saw Solid Growth in 2017
In 4Q17, Eli Lilly’s (LLY) Taltz generated revenues of $172.5 million compared to $61.3 million in 4Q16.
What Are Analysts’ Recommendations for Merck in 2017?
For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.
Johnson & Johnson’s Valuation Cheat Sheet
On January 26, 2017, the company was trading at a forward PE of ~15.8x. Based on the last five years’ multiple range, JNJ’s current valuation is neither high nor low.
What Analysts Think about Bristol-Myers Squibb
Of 28 analysts covering BMY’s stock, 42.3% gave it a “buy” recommendation, while 50.0% gave it a “hold” recommendation. Only 7.7% rated it as a “sell.”
Analysts’ Expectations for Sanofi
According to a March 3, 2016, Bloomberg consensus of five brokerage firms, 60% of brokerage firms rated Sanofi as a “buy,” while 40% of the broker firms rated the company as a “hold.”
What Analysts Project for Eli Lilly in 3Q17
For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.
Inside XLV’s Large Caps: Pfizer’s 1Q16 Earnings
Pfizer recently rose by 2.7% on revenues of $13 billion for 1Q16, as compared to $10.9 billion in 1Q15, which represents a growth of 20% YoY.
Label Expansion Expected to Boost Keytruda’s 2017 Revenue
On October 24, 2016, the FDA approved Merck & Co’s (MRK) Keytruda as a second-line therapy for patients suffering from non-small cell lung cancer (or NSCLC).
Pfizer Missed Analysts’ Third-Quarter Revenue Estimates
Pfizer (PFE) released its third-quarter earnings on October 30.
Assessing Novartis’s Performance in October So Far
Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.
Highfields Capital exits its position in Broadcom
Highfields Capital sold its position in BRCM in the third quarter. The position accounted for 1.66% of the fund’s 2Q14 portfolio. Broadcom makes semiconductors for wired and wireless communications.
Valeant’s Dermatology Business Felt Pricing Pressure in 2016
Dermatology pricing trends Valeant Pharmaceuticals’ (VRX) dermatology business witnessed intense pricing pressure in 2016, due to a change in the company’s distribution model in 4Q15. While Valeant previously marketed its dermatology drugs through specialty pharmacies, the company now distributes its products through Walgreens. To learn about the company’s current distribution model, please refer to How Valeant Plans […]
Siliq May be a Strong Growth Driver for Valeant in 2017
Siliq growth trends On February 15, 2017, the FDA approved injectable biologic therapy Siliq (brodalumab) as a treatment option for moderate-to-severe plaque psoriasis patients. Siliq is for psoriasis patients eligible for systemic therapy or phototherapy, and are not responding sufficiently or have stopped responding to these treatment options. To learn more about Siliq, please refer to What Are […]
Wall Street Analysts: Mostly Positive on Opko Health in July
On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March.
Why Incyte Stock Fell ~9% on April 24
On April 24, Incyte (INCY) stock fell ~9% on news regarding its drug Baricitinib, which is under FDA review.
Mylan Launches First Adcirca Generic, Stock Moves Up
Mylan Pharmaceuticals (MYL) announced the launch of tadalafil tablets USP (20 mg) in the United States.
A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta
In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.
Biogen Pursuing Investigational Candidates in Alzheimer’s Disease
Biogen (BIIB) has entered into a licensing agreement with Bristol-Myers Squibb (BMY) for exclusive global rights for the development and commercialization of BMS-986168.
What to Expect from Pfizer’s 2Q16 Earnings
In Pfizer’s 2Q16 results, analysts expect to see EPS (or earnings-per-share) of $0.62 and revenues of ~$13.0 billion for 2Q16. The company has surpassed Wall Street analysts’ estimates for EPS over the last few quarters.
Investor Insights: Teva Pharmaceutical’s Valuation Multiples
On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x.
Novo Nordisk Is Focusing on These Strategic Areas in 2016
With 642 million people expected to suffer from diabetes globally by 2040, the disease is expected to offer multiple growth opportunities for Novo Nordisk.
Teva Stock Rises on Strong 1Q18 Results, Outlook Up
Today, Teva Pharmaceutical Industries (TEVA) released its 1Q18 earnings results for the quarter that ended on March 31.
Amgen: Exploring Opportunities in the Bone Segment
Amgen’s Prolia is the leading brand for treating postmenopausal osteoporosis, or PMO, in women with a high risk of bone fracture.
Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer
Since its launch in February 2015, Pfizer’s Ibrance has quickly captured the advanced breast cancer market and has reached more than 40,000 patients.
Analysts’ Recommendations for Sanofi Stock before Q2 Results
Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31.
How Analysts Rate Bristol-Myers Squibb in 1Q18
Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18.
Why AstraZeneca’s oncology pipeline is attractive to Pfizer
Pfizer (PFE) is seeking to expand its oncology franchise and a combination with AstraZeneca (AZN) would be meaningful due to the latter’s pipeline of cancer drugs.
Eli Lilly’s Valuation on May 17
On May 17, Eli Lilly was trading at a forward PE multiple of 15.2x, which compares to the industry average of 13.6x.
GlaxoSmithKline Increases Top Line in 2Q16
GlaxoSmithKline (GSK) reported a 10.9% increase in its top line in its 2Q16 earnings on July 27, 2016. It met Wall Street analysts’ estimates for revenues and EPS.
Novartis Receives 2 Breakthrough Therapy Designations in January
In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.
European Medicines Agency Validates Merck’s Keytruda Combo
Merck’s (MRK) Keytruda (pembrolizumab) is approved to treat various forms of cancer.
Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug
On September 21, 2016, the FDA approved Jannsen Pharmaceuticals’ Invokamet XR for the treatment of adults suffering from Type 2 diabetes.
Competition Dynamics for Ajovy—Teva’s Migraine Drug
Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.
An Overview of Valeant Pharmaceuticals’ Performance in 1Q18
Valeant Pharmaceuticals (VRX) announced that it would change its name to Bausch Health Companies, which is expected to be effective in July.
Eli Lilly’s 1Q18 Earnings: Neuroscience Products Portfolio
Cymbalta, an antidepressant drug, reported revenues of $169.6 million in 1Q18, a 3% growth compared to $174.6 million in 1Q17.
Non-Opioid Pain Therapy Market Opportunity for Teva
The Trump administration proposed production cuts in some of the most abused opioid compounds by 10% next year.
Overview: Highbridge Capital Management’s 2Q14 positions
Highbridge Capital Management is an alternative investment management organization. It was founded in 1992. The company has developed a diversified investment platform.
Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
Januvia and Janument: An Update on Merck’s Diabetes Franchise after 2Q17
In 2Q17, Merck’s (MRK) Januvia generated revenues of around $948 million, which reflected an ~11% decline on a year-over-year basis and 13% growth on a quarter-over-quarter basis.
Novo Nordisk Continues to Be a Leader in the Global Insulin Market
Accounting for a ~46% market share, Novo Nordisk (NVO) is expected to continue to benefit from the positive trends in the global insulin market
Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance
Eli Lilly and Co. reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17.
Opdivo Is a Key Growth Driver for Bristol-Myers Squibb in 2016
On November 10, 2016, the FDA approved Opdivo as a treatment option for patients suffering with recurring or metastatic squamous cell carcinoma of the head and neck (or SCCHN).
Sanofi Stock: How Much Upside Potential Does Wall Street See?
In the second quarter of fiscal 2018, Sanofi (SNY) reported sales of 8.2 billion euros, a YoY (year-over-year) decline in sales as well as profits.
Entering Migraine Market Won’t Be Easy for Novartis, Amgen
Novartis (NVS) and Amgen (AMGN) recently announced that the CGRP inhibitor therapy, AMG 334, reported positive results in a Phase 2 clinical trial as a therapy for preventing chronic migraine.
What Will Be a Key Driver of Biogen’s Future Valuations?
Biogen’s investigational Alzheimer’s disease drug, aducanumab, is one of the four therapies accepted in the EMA’s Priority Medicines program (or PRIME).
Mylan’s Recent Acquisitions Continue to Strengthen Its Position in International Markets
Mylan takes an M&A strategy to save time related to compliance activities for obtaining regulatory approvals across various international markets.
Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18
Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.
How Merial Contributes to Sanofi’s Growth
Merial, Sanofi’s (SNY) Animal Health segment, reported total revenues of 725 million euros (about $818.6 million), which is a 9.1% increase over 2Q15.
Must-know: Highfields Capital exits a position in Exxon Mobil
Highfields Capital exited a position in Exxon Mobil that accounted for 1.67% of the fund’s 1Q14 (or the first quarter of 2014) portfolio.
Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
Merck’s Relebactam is an investigational drug for the treatment of certain forms of imipenem-non-susceptible bacterial infections.
Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates
Bristol-Myers Squibb beat Wall Street analysts’ estimates for earnings per share and revenues in 1Q18.
Brodalumab, Oral Relistor among Valeant’s Recent Wins
Valeant’s (VRX) recent wins include the FDA’s advisory committee vote in favor of approving brodalumab for the indication of mild to moderate psoriasis.
Eli Lilly’s 1Q18 Earnings: Cardiovascular Products Portfolio
Eli Lilly’s (LLY) Human Pharmaceuticals business includes cardiovascular products Effient, Cialis, and Adcirca, which reported lower sales in 1Q18.
Highfields Capital Management’s positions in 3Q14
Highfields Capital Management LP is based in Boston. The fund was founded by Jonathon Jacobson in 1998. The fund’s US long portfolio declined slightly to $12.8 billion in the third quarter.
The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug
On October 17, 2016, Teva and Regeneron announced that the FDA had placed the Phase 2 study for fasinumab on clinical hold.
Olumiant Could Boost Incyte’s Revenues
In February 2017, Eli Lilly (LLY) secured approval for Olumiant (baricitinib) from the European Medicines Agency (or EMA) for patients suffering from moderate-to-severe rheumatoid arthritis.
Must-know: Highfields Capital starts a new position in Eli Lilly
Highfields Capital initiated a new position in Eli Lilly and Company that accounts for 2.13% of the fund’s 2Q14 (or second quarter of 2014) portfolio.
Pfizer Reports 1Q18 Earnings and Revenue Growth
Pfizer (PFE) released its 1Q18 earnings today, reporting another strong quarter for the Innovative health business.
Major M&A Deals in Pharmaceutical Sector in May and June
On June 1, GlaxoSmithKline (GSK) completed the buyout of a 36.5% stake in Novartis (NVS) in a consumer healthcare joint venture.
How Did Merial Contribute to Sanofi’s 2Q15 Growth?
Merial reported total revenues of 691 million euros, a 14.2% increase at constant exchange rates over 2Q14.
Ligand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst
Ligand Pharmaceuticals’s (LGND) product portfolio has expanded from nine programs in 2008 to 140+ programs in 2016.
Maverick Capital Increases Stake in Novartis
Maverick Capital increased its position in Novartis (NVS) by more than $22 million in stock. It represented 0.75% of the fund’s total portfolio in 4Q14.
Teva Announces First-to-File Launch of Generic Cialis
Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.
How’s Celgene’s Abraxane Positioned after 4Q17?
In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.
Why the US Moat Index Beat the S&P 500 Index in July
Domestic moat companies, as represented by the Morningstar® Wide Moat Focus IndexSM (MWMFTR, or “U.S. Moat Index”), once again posted strong results in July.
Should You Buy Eli Lilly Stock After Its Q3 Earnings?
Trump Pushes Regeneron and Eli Lilly Antibodies for COVID-19, Stocks Up
Why the Patent Cliff Is a Key Driver of Generic Drug Growth
Over the last several years, patent cliffs have led to steep revenue losses for traditional pharmaceuticals as well as created a gateway for smaller companies to come to market with generics.
Why Eli Lilly Expects 2Q17 Revenue Growth
As per analysts’ estimates, Eli Lilly’s (LLY) revenues could rise ~3.6% to $5.6 billion in 2Q17.
A Financial Overview of Bausch Health in October
Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.
How Eli Lilly’s Cardiovascular Products Have Been Faring
Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes cardiovascular products such as Cialis, Effient, and other products.
These Pharma Stocks Offer the Most Upside Potential
In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.
Wall Street Analysts Are Mostly Positive about Johnson & Johnson
In June, Johnson & Johnson (JNJ) accepted a binding offer from Platinum Equity to acquire its LifeScan business for ~$2.1 billion.
Three Black Crows And Three White Soldiers Candlestick Pattern
The Three White Soldiers candlestick pattern is also a reversal pattern. It forms at the bottom of a downtrend. The pattern has three candles. All three of the candles are long and bullish.
Zoetis: An attractive business model
Zoetis said in a recent statement that “its unique characteristics have established the company as the world leader in animal health, growing revenue faster than the market for the last three years.”
Must-know trends that drive Zoetis’ growth
Demand for Zoetis’ products is driven by a growing population coupled with a rising middle class in emerging markets and increased relocation from rural to urban areas.
Amgen has attractive, high-growth assets
The principal products represented 92% of Amgen’s worldwide product sales for the first half of 2014. Total product sales in 3Q14 rose 4% year-over-year, mainly driven by Kyprolis, Prolia, Neulasta, and Xgeva.
Wellington Management: Analyzing Its Top Holdings
Wellington Management filed its 13F on Wednesday. Based on the filing, the market value of total publicly traded securities was around $443.45 billion.
How Are Citadel Advisors Hedging their Portfolio?
Kenneth Cordele Griffin is the CEO of investment management firm Citadel Advisors LLC. He is the hedge fund manager and he founded Citadel in 1990.
Must-know: How does Box make money?
The company states that it has over 34,000 paying organizations registered.
Ignyta’s Drug Pipeline
Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.
Tech Movers: Fitbit, Roku, and Datadog Lead Gains
The broader markets were subdued today. However, tech stocks Datadog (DDOG), Roku (ROKU) and Fitbit (FIT) gained significantly. Here’s why.
New Apple Watch Features to Focus on Digital Health
Apple (AAPL) has partnered with Eli Lily (LLY) to research whether the iPhone and Apple Watch can identify Alzheimer’s and dementia among users.
Pain and Immunology: Eli Lilly’s Key Growth Areas
In the first quarter, Emgality, Eli Lilly and Company’s (LLY) migraine prophylaxis drug, reported revenue of $14 million, of which $12.0 million came from the US market.
How Is Eli Lilly’s Revenue Trending in 2019?
During its first-quarter earnings investor presentation, Eli Lilly and Company (LLY) guided for revenue of $22.0 billion–$22.5 billion in 2019.
What Analysts Recommend for LLY and AMGN
Eli Lilly and Company (LLY) is down 0.20%, and Amgen (AMGN) is down 3.88% in 2019 on a year-to-date basis. Investors seem disappointed with the first-quarter results of both companies.
A Look at Cosentyx, Novartis’s Fast-Growing Immunology Drug
In the first quarter, Novartis’s (NVS) Cosentyx reported net sales of $791 million, a YoY (year-over-year) rise of 41% on a constant currency basis.
A Look at AstraZeneca’s and Eli Lilly’s Tax and Debt
In fiscal 2018, AstraZeneca (AZN) and Eli Lilly (LLY) reported effective tax rates of 3% and $15.98%, respectively.
AstraZeneca or Eli Lilly: Which Is Controlling Expenses Better?
In its fourth-quarter earnings press release, AstraZeneca (AZN) guided for a low single-digit YoY (year-over-year) rise in core operating expenses in fiscal 2019.
What’s Expected for AstraZeneca’s or Eli Lilly’s EPS Growth
In its fourth-quarter earnings investor presentation, AstraZeneca (AZN) guided for core EPS of $3.50–$3.70 in fiscal 2019, expecting robust YoY (year-over-year) product sales growth and productivity improvements.
What are AstraZeneca’s Key Growth Drivers?
In fiscal 2018, AstraZeneca’s (AZN) revenue fell 2% YoY (year-over-year) to $22.09 billion on a CER (constant-exchange-rate) and reported basis.
Roche Holdings to Acquire Spark Therapeutics
On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).
What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?
On its fourth-quarter earnings conference call, Teva Pharmaceutical (TEVA) highlighted Ajovy and Austedo as its key growth drivers for 2019.